Top

European Journal of Nuclear Medicine and Molecular Imaging

Published in:

01-10-2013 | Original Article

Diagnostic usefulness of ¹⁸F-FAMT PET and L-type amino acid transporter 1 (LAT1) expression in oral squamous cell carcinoma

Authors: Aiko Nobusawa, Mai Kim, Kyoichi Kaira, Go Miyashita, Akihide Negishi, Noboru Oriuchi, Tetsuya Higuchi, Yoshito Tsushima, Yoshikatsu Kanai, Satoshi Yokoo, Tetsunari Oyama

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 11/2013

Abstract

Purpose

l-[3-¹⁸F]-α–Methyltyrosine (¹⁸F-FAMT) was developed as an amino acid tracer for PET imaging to provide better specificity than 2-[¹⁸F]fluoro-2-deoxy-d-glucose (¹⁸F-FDG) PET for cancer diagnosis. We investigated the diagnostic usefulness of ¹⁸F-FAMT in oral squamous cell carcinoma (OSCC). The correlation between tumour uptake of ¹⁸F-FAMT and L-type amino acid transporter 1 (LAT1) expression was determined.

Methods

The study group comprised 68 OSCC patients who underwent both ¹⁸F-FAMT and ¹⁸F-FDG PET. Resected tumour sections were stained by immunohistochemistry for LAT1, CD98 and Ki-67, and microvessel density was determined in terms of CD34 and p53 expression.

Results

The sensitivity of primary tumour detection by ¹⁸F-FAMT and ¹⁸F-FDG PET was 98 % and 100 %, respectively. The sensitivity, specificity and accuracy of ¹⁸F-FAMT PET for detecting malignant lymph nodes were 68 %, 99 % and 97 %, respectively, and equivalent values for ¹⁸F-FDG PET were 84 %, 94 % and 94 %, respectively. The specificity and accuracy of ¹⁸F-FAMT were significantly higher than those of ¹⁸F-FDG. The uptake of ¹⁸F-FAMT was significantly correlated with LAT1 expression, cell proliferation and advanced stage. The expression of LAT1 in OSCC cells was closely correlated with CD98 levels, cell proliferation and angiogenesis.

Conclusion

¹⁸F-FAMT PET showed higher specificity for detecting malignant lesions than ¹⁸F-FDG PET. The uptake of ¹⁸F-FAMT by OSCC cells can be determined by the presence of LAT1 expression and tumour cell proliferation.

Available only for authorised users

Kaira K, Endo M, Abe M, Nakagawa K, Ohde Y, Okumura T, et al. Biologic correlation of 2-[18F]-fluoro-2-deoxy-D-glucose uptake on positron emission tomography in thymic epithelial tumors. J Clin Oncol. 2010;28:3746–53.PubMedCrossRef

Kaira K, Serizawa M, Koh Y, Takahashi T, Hanaoka H, Oriuchi N, et al. Relationship between 18F-FDG uptake on positron emission tomography and molecular biology in malignant pleural mesothelioma. Eur J Cancer. 2012;48:1244–54.PubMedCrossRef

Kaira K, Oriuchi N, Otani Y, Yanagitani N, Sunaga N, Hisada T, et al. Diagnostic usefulness of fluorine-18-alpha-methyltyrosine positron emission tomography in combination with 18F-fluorodeoxyglucose in sarcoidosis patients. Chest. 2007;131:1019–27.PubMedCrossRef

Tomiyoshi K, Amed K, Muhammad S, Higuchi T, Inoue T, Endo K, et al. Synthesis of isomers of 18F-labelled amino acid radiopharmaceutical: position 2- and 3-L-18F-alpha-methyltyrosine using a separation and purification system. Nucl Med Commun. 1997;18:169–75.PubMedCrossRef

Wiriyasermkul P, Nagamori S, Tominaga H, Oriuchi N, Kaira K, Nakao H, et al. Transport of 3-fluoro-L-α-methyl-tyrosine by tumor-upregulated L-type amino acid transporter 1: a cause of the tumor uptake in PET. J Nucl Med. 2012;53:1253–61.PubMedCrossRef

Kaira K, Oriuchi N, Otani Y, Shimizu K, Tanaka S, Imai H, et al. Fluorine-18-alpha-methyltyrosine positron emission tomography for diagnosis and staging of lung cancer: a clinicopathologic study. Clin Cancer Res. 2007;13:6369–78.PubMedCrossRef

Inoue T, Shibasaki T, Oriuchi N, Aoyagi K, Tomiyoshi K, Amano S, et al. 18F-α-methyl tyrosine PET studies in patients with brain tumors. J Nucl Med. 1999;40:399–405.PubMed

Miyashita G, Higuchi T, Oriuchi N, Arisaka Y, Hanaoka H, Tominaga H, et al. 18F-FAMT uptake correlates with tumor proliferative activity in oral squamous cell carcinoma: comparative study with 18F-FDG PET and immunohistochemistry. Ann Nucl Med. 2010;24:579–84.PubMedCrossRef

Sohda M, Kato H, Suzuki S, Tanaka N, Sano A, Sakai M, et al. 18F-FAMT-PET is useful for the diagnosis of lymph node metastasis in operable esophageal squamous cell carcinoma. Ann Surg Oncol. 2010;17:3181–6.PubMedCrossRef

10.

Isoda A, Higuchi T, Nakano S, Arisaka Y, Kaira K, Kamio T, et al. 18F-FAMT in patients with multiple myeloma: clinical utility compared to 18F-FDG. Ann Nucl Med. 2012;26:811–6.PubMedCrossRef

11.

Miyakubo M, Oriuchi N, Tsushima Y, Higuchi T, Koyama K, Arai K, et al. Diagnosis of maxillofacial tumor with L-3-[18f]-fluoro-alpha-methyltyrosine (FMT) PET: a comparative study with FDG-PET. Ann Nucl Med. 2007;21:129–35.PubMedCrossRef

12.

Watanabe H, Inoue T, Shinozaki T, Yanagawa T, Ahmed AR, Tomiyoshi K, et al. PET imaging of musculoskeletal tumours with fluorine-18 alpha-methyltyrosine: comparison with fluorine-18 fluorodeoxyglucose PET. Eur J Nucl Med. 2000;27:1509–17.PubMedCrossRef

13.

Kanai Y, Segawa H, Miyamoto K, Uchino H, Takeda E, Endou H. Expression cloning and characterization of a transporter for large neutral amino acids activated by the heavy chain of 4F2 antigen (CD98). J Biol Chem. 1998;273:23629–32.PubMedCrossRef

14.

Yanagida O, Kanai Y, Chairoungdua A, Kim DK, Segawa H, Nii T, et al. Human L-type amino acid transporter 1 (LAT 1): characterization of function and expression in tumor cell lines. Biochim Biophys Acta. 2001;1514:291–302.PubMedCrossRef

15.

Nakanishi K, Ogata S, Matsuo H, Kanai Y, Endou H, Hiroi S, et al. Expression of LAT1 predicts risk of progression of transitional cell carcinoma of the upper urinary tract. Virchows Arch. 2007;451:681–90.PubMedCrossRef

16.

Nawashiro H, Otani N, Shinomiya N, Fukui S, Ooigawa H, Shima K, et al. L-type amino acid transporter 1 as a potential molecular target in human astrocytic tumors. Int J Cancer. 2006;119:484–92.PubMedCrossRef

17.

Sakata T, Ferdous G, Tsuruta T, Satoh T, Baba S, Muto T, et al. L-type amino acid transporter 1 as a novel biomarker for high-grade malignancy in prostate cancer. Pathol Int. 2009;59:7–18.PubMedCrossRef

18.

Ichinoe M, Mikami T, Yoshida T, Igawa I, Tsuruta T, Nakada N, et al. High expression of L-type amino-acid transporter 1 (LAT1) in gastric carcinomas: comparison with non-cancerous lesions. Pathol Int. 2011;61:281–9.PubMedCrossRef

19.

Kaira K, Oriuchi N, Imai H, Shimizu K, Yanagitani N, Sunaga N, et al. Prognostic significance of L-type amino acid transporter 1 expression in resectable stage I-III nonsmall cell lung cancer. Br J Cancer. 2008;98:742–8.PubMedCrossRef

20.

Furuya M, Horiguchi J, Nakajima H, Kanai Y, Oyama T. Correlation of L-type amino acid transporter 1 and CD98 expression with triple negative breast cancer prognosis. Cancer Sci. 2012;103:382–9.PubMedCrossRef

21.

Kaira K, Sunose Y, Arakawa K, Ogawa T, Sunaga N, Shimizu K, et al. Prognostic significance of L-type amino-acid transporter 1 expression in surgically resected pancreatic cancer. Br J Cancer. 2012;107:632–8.PubMedCrossRef

22.

Kaira K, Oriuchi N, Takahashi T, Nakagawa K, Ohde Y, Okumura T, et al. LAT1 expression is closely associated with hypoxic markers and mTOR in resected non-small cell lung cancer. Am J Transl Res. 2011;3:468–78.PubMed

23.

Kaira K, Oriuchi N, Shimizu K, Ishikita T, Higuchi T, Imai H, et al. Evaluation of thoracic tumors with 18F-FMT and 18F-FDG PET-CT: a clinicopathological study. Int J Cancer. 2009;124:1152–60.PubMedCrossRef

24.

Kaira K, Oriuchi N, Shimizu K, Tominaga H, Yanagitani N, Sunaga N, et al. 18F-FMT uptake seen within primary cancer on PET helps predict outcome of non-small cell lung cancer. J Nucl Med. 2009;50:1770–6.PubMedCrossRef

25.

Pauleit D, Zimmermann A, Stoffels G, Bauer D, Risse J, Flüss MO, et al. 18F-FET PET compared with 18F-FDG PET and CT in patients with head and neck cancer. J Nucl Med. 2006;47:256–61.PubMed

26.

Sutinen E, Jyrkkiö S, Alanen K, Någren K, Minn H. Uptake of [N-methyl-11C]alpha-methylaminoisobutyric acid in untreated head and neck cancer studied by PET. Eur J Nucl Med Mol Imaging. 2003;30:72–7.PubMedCrossRef

27.

Troost EG, Vogel WV, Merkx MA, Slootweg PJ, Marres HA, Peeters WJ, et al. 18F-FLT PET does not discriminate between reactive and metastatic lymph nodes in primary head and neck cancer patients. J Nucl Med. 2007;48:726–35.PubMedCrossRef

28.

Krabbe CA, van der Werff-Regelink G, Pruim J, van der Wal JE, Roodenburg JL. Detection of cervical metastases with 11C-tyrosine PET in patients with squamous cell carcinoma of the oral cavity or oropharynx: a comparison with 18F-FDG PET. Head Neck. 2010;32:368–74.PubMed

29.

Tian M, Zhang H, Nakasone Y, Mogi K, Endo K. Expression of Glut1 and Glut3 in untreated oral squamous cell carcinoma compared with FDG accumulation in a PET study. Eur J Nucl Med Mol Imaging. 2004;31:5–12.PubMedCrossRef

30.

Li SJ, Guo W, Ren GX, Huang G, Chen T, Song SI. Expression of Glut-1 in primary and recurrent head and neck squamous cell carcinomas, and compared with 2-[18F]fluoro-2-deoxy-D-glucose accumulation in positron emission tomography. Br J Oral Maxillofac Surg. 2008;46:180–6.PubMedCrossRef

31.

Han MW, Lee HJ, Cho KJ, Kim JS, Roh JL, Choi SH, et al. Role of FDG-PET as a biological marker for predicting the hypoxic status of tongue cancer. Head Neck. 2012;34:1395–402.PubMedCrossRef

32.

Fuchs BC, Bode BP. Amino acid transporters ASCT2 and LAT1 in cancer: partners in crime? Semin Cancer Biol. 2006;15:254–66.CrossRef

33.

Imai H, Kaira K, Oriuchi N, Shimizu K, Tominaga H, Yanagitani N, et al. Inhibition of L-type amino acid transporter 1 has antitumor activity in non-small cell lung cancer. Anticancer Res. 2010;30:4819–28.PubMed

34.

Kim CS, Cho SH, Chun HS, Lee SY, Endou H, Kanai Y, et al. BCH, an inhibitor of system L amino acid transporters, induces apoptosis in cancer cells. Biol Pharm Bull. 2008;31:1096–100.PubMedCrossRef

Title: Diagnostic usefulness of 18F-FAMT PET and L-type amino acid transporter 1 (LAT1) expression in oral squamous cell carcinoma
Authors: Aiko Nobusawa
Mai Kim
Kyoichi Kaira
Go Miyashita
Akihide Negishi
Noboru Oriuchi
Tetsuya Higuchi
Yoshito Tsushima
Yoshikatsu Kanai
Satoshi Yokoo
Tetsunari Oyama
Publication date: 01-10-2013
Publisher: Springer Berlin Heidelberg
Published in: European Journal of Nuclear Medicine and Molecular Imaging / Issue 11/2013
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-013-2477-9

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Diagnostic usefulness of ¹⁸F-FAMT PET and L-type amino acid transporter 1 (LAT1) expression in oral squamous cell carcinoma

Abstract

Purpose

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 11/2013

Real-time FDG PET/CT-guided bone biopsy in a patient with two primary malignancies

Somatostatin receptor PET/CT in neuroendocrine tumours: update on systematic review and meta-analysis

Positron emission tomography based in-vivo imaging of early phase stem cell retention after intramyocardial delivery in the mouse model

Rapid optical imaging of human breast tumour xenografts using anti-HER2 VHHs site-directly conjugated to IRDye 800CW for image-guided surgery

Robustness of intratumour 18F-FDG PET uptake heterogeneity quantification for therapy response prediction in oesophageal carcinoma

Clinical significance of VEGFR-2 and 18F-FDG PET/CT SUVmax pretreatment score in predicting the long-term outcome of patients with locally advanced rectal cancer treated with neoadjuvant therapy